SAN DIEGO, Sept. 18 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA - News), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today the first-in-human U.S. use of its NeoDisc cervical disc replacement device. The first procedure is part of a prospective, randomized, controlled, multi-center clinical trial to evaluate the safety and efficacy of NeoDisc by comparing the outcomes of patients to traditional anterior cervical discectomy and fusion. This first implantation is ahead of the company's guidance to begin enrollment by the fourth quarter.
